Founded in 2020 as a spin-out company from Aalborg University, NEUmiRNA Therapeutics’ mission is to transform the lives of patients with severe neurological diseases through new and innovative RNA medicines. NEUmiRNA Therapeutics’ interest is neurological diseases with a major unmet medical need – mainly focused on 2 therapeutic areas: Epilepsy and Parkinson’s Disease.

Current treatments to epilepsy like anti-seizure medication are limited as they only treat symptoms of epilepsy and not the disease itself nor its comorbidities. Furthermore, up to 30% of epilepsy patients develop resistance towards the medicine, leaving them without any treatment options.

Parkinson’s Disease is a neurological disorder affecting the nervous system causing the brain to slowly degenerate. Just like Epilepsy, there is no cure for Parkinson’s Disease, only symptom-relieving medicine.

UTILIZING ANTI-MIRNA FOR THERAPEUTIC TREATMENT

The core of NEUmiRNA Therapeutics is an RNA drug platform technology able to target specific neurological disorders by utilizing anti-microRNA (anti-miRNA) oligonucleotides to target dysfunctional microRNA (miRNA) molecules.

MiRNAs are small, non-coding RNA molecules that regulate cellular functions through the regulation of gene expression. If an over-/under expression or aberration in the miRNA occurs, it can lead to a range of disorders. Beside neurological diseases, some of the miRNA-linked disorders are cancer, muscular diseases, autoimmune disorders, and a range of viral infections.

Contrary, anti-miRNAs are designed to control and neutralize specific miRNAs for desired responses. By uncovering the miRNA sequences involved in the before mentioned disorders, the unique mechanism of anti-miRNAs can be used to disrupt the pathways leading to the under-/over expression or aberration of the miRNAs causing the disorders.